Yujiro S. Hata

Board Member at Expansion Therapeutics

Mr. Hata serves as Chief Executive Officer at Ideaya, a 5AM portfolio company developing therapeutics for oncology. From 2014 to August 2015, Yujiro served as Chief Operating Officer at immuno-oncology companies Flexus Biosciences and its spinout FLX Bio. He joined Flexus as a startup and led the company through its acquisition by Bristol-Myers Squibb in April 2015. While at Flexus, Yujiro oversaw all business operations, corporate strategy and M&A and licensing. From 2010 through its acquisition in October 2013 by Amgen, Mr. Hata was Vice President, Corporate Development & Strategy at Onyx Pharmaceuticals, where he held various leadership roles including Head of Strategy and Strategic Asset Management and Head of M&A and Licensing. From 2002 to 2010, Mr. Hata served as Vice President, Senior Vice President and Chief Business Officer at Enanta Pharmaceuticals (NASDAQ: ENTA). He earlier served in roles spanning business and R&D at McKinsey & Company, ImClone and Columbia Medical School. Mr. Hata obtained his MBA at Wharton, as a Henry J Kaiser recipient, and completed undergraduate studies in chemistry at Oxford University and Colorado College. He serves on the Board of Directors of Xencor (NASDAQ: XNCR) and the Board of Visitors of the Moores Cancer Center, at the University of California, San Diego. Mr. Hata is based in the San Francisco, CA office.


  • Board Member

    Current role


By clicking "Continue" or continuing to use our site, you acknowledge that you accept our Privacy Policy and Terms of Use. We also use cookies to provide you with the best possible experience on our website.